Membrane Target Detection for Leukemia Treatment

Part of paid clinical trials in Columbia, Missouri.

Sponsor
University of Missouri-Columbia
Study ID
NCT04841447
Status
Recruiting
Apply to this trial

Conditions

  • Hematological Malignancy

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Study sample collection — OTHER
    Peripheral blood draws and bone marrow aspiration will be done during clinic visit and hospital stay.

Study Details

Acute myeloid leukemia (AML) accounts for more than 40% of leukemia mortality in the United States. Each year around ten thousand people die from the disease, most within a few years of diagnosis. Despite advances in our understanding of the disease, few improvements in the therapy of AML have been made. Collecting specimens from the blood and bone marrow will increase understanding of the effect of Dipeptidyl Peptidase-4 (DPP-4) Inhibitors on human AML-SCP to develop individualized therapies. We also found DPP4 is highly expressed in other hematological malignancies in our mouse model, thus we would like to use human samples to investigate the role of DPP4 in hematological malignancy development and the mechanism underlying, especially to deeply understand the role of DDP4 in leukemia.

Key Dates

Start date
Mar 20, 2020
Status verified
Dec 2025
Primary completion
Mar 20, 2027
Completion
Mar 20, 2027

Study Design

Enrollment
50 participants (estimated)

Primary Outcome Measure

DPP4 inhibitors measured in blood samples will be correlated with patient survival data. [ Time Frame: 5 years ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
University of MissouriColumbiaMissouri65212
Xunlei Kang, MD.PhD
[email protected]
5738844524

Find similar trials in Columbia, MO

By research site
University of Missouri· Columbia, MO

Related Studies